Lee S. Schwartzberg MD, FACP
Medical Director, West Cancer Center, Memphis, Tennessee; Chief Medical Officer, OneOncologyLee S. Schwartzberg, MD, FACP, is professor of medicine at The University of Tennessee Health Science Center in Memphis, Chief Medical Officer at OneOncology, and medical director of the West Cancer Center, as well as a practicing medical oncologist.
Upon earning his MD degree from the New York Medical College in Valhalla, NY, Dr Schwartzberg completed an internship and a residency in internal medicine at the Cornell University North Shore University Hospital in Manhasset, NY. He then served as chief resident at Memorial Sloan Kettering Cancer Center in New York City and completed a fellowship in medical oncology/hematology.
The author or coauthor of more than 250 publications on medical oncology, hematology, and biosimilars, Dr Schwartzberg has been a leader in and educating healthcare professionals about the potential benefits of biosimilars in oncology practice. He has been very active in the work of the National Comprehensive Cancer Network, having served on its Board of Directors, the Guideline Steering Committee, and the Breast Cancer Guideline Panel, among others. He is past founding chairman of the Association of Community Cancer Centers Immuno-Oncology Institute and the editor-in-chief of the website PracticeUpdate Oncology.
Positions:
Medical Director, West Cancer Center, Memphis, Tennessee
Chief Medical Officer, OneOncology
Degrees:
State University of New York, BA and MS
New York Medical College, MD, FACP
Postgraduate Training:
Intern, North Shore University Hospital, Manhasset, NY
Fellow in medical oncology/hematology, Memorial Sloan-Kettering Cancer Center
Board Certifications:
Medical oncology
Hematology
Clinical Interests:
Medical oncology/hematology
Disclosures
He is a consultant for Amgen, Pfizer, Helsinn, Genentech, BMS, Myriad, AstraZeneca, Spectrum, and Napo.
He is also on the advisory board for Genomic Health Research Funding (Institution): Amgen and DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Filgrastim vs Filgrastim Biosimilars for Prevention of Febrile Neutropenia
- Overall Survival With Fulvestrant Plus Anastrozole in Metastatic Breast Cancer
- Real-World Efficacy of Palonosetron Three-Drug Regimen for Highly Emetogenic Chemotherapy
- FDA Approves Atezolizumab for PD-L1 Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- Increasing the Dose Intensity of Chemotherapy by More Frequent Administration or Sequential Scheduling
- Olaparib vs Chemotherapy in Patients With a Germline BRCA Mutation and HER2-Negative Metastatic Breast Cancer
- Underdiagnosis of Hereditary Breast Cancer
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- Lasofoxifene vs Fulvestrant for HR-Positive Breast Cancer